Hot Sliver Companies To Watch In Right Now

By and large, the S&P 500 Index (SNPINDEX: ^GSPC  ) was able to shrug off weak earnings from the technology sector and the benchmark index even posted its fourth straight week of gains and finished at an all-time high on Friday. Not bad for a day that saw tens of billions of dollars disappear in a matter of hours from today's three biggest laggards alone. By the end of the day, the S&P had added 2 points, or 0.2%, to end at 1,692. The following three companies, however, lost their proverbial shirts.�

Advanced Micro Devices (NYSE: AMD  ) leads off this ignominious list after plummeting 13.2%. The chip maker reported earnings yesterday, and despite beating analyst expectations for the quarter, the shares were promptly downgraded by two analysts today. That's Wall Street for ya. To be fair, the company did swing to a loss and gross margins fell. Analysts were mostly concerned with AMD's gaming revenues moving forward.

By far the biggest name on today's list, however, is Microsoft (NASDAQ: MSFT  ) , as shares in the software maker cratered 11.4%, the largest one-day slip shares have experienced since 2009. Like AMD, disappointing quarterly results prompted a flurry of analyst downgrades and price target decreases. What worried investors most were signs of a slumping Windows division, the cash cow and backbone of the business. The slow demise of PCs is starting to look like a very real and immediate threat to Microsoft's vitality.

Top 5 Financial Companies To Buy For 2015: Prudential Financial Inc.(PRU)

Prudential Financial, Inc., through its subsidiaries, offers various financial products and services in the United States, Asia, Europe, and Latin America. The company operates through three divisions: The U.S. Retirement Solutions and Investment Management, The U.S. Individual Life and Group Insurance, and The International Insurance and Investments. The U.S. Retirement Solutions and Investment Management division provides individual variable and fixed annuity products, as well as offers retirement investment and income products and services to retirement plan sponsors in the public, private, and not-for-profit sectors. This division also provides investment management and advisory services to the public and private marketplace. The U.S. Individual Life and Group Insurance division offers individual variable life, term life, and universal life insurance products; and group life, long-term and short-term group disability, long-term care, and group corporate-, bank-and trus t-owned life insurance products to institutional clients. This division also sells accidental death and dismemberment, and other ancillary coverages, as well as provides plan administrative services; and offers preferred provider and indemnity dental coverage plans to clients. The International Insurance and Investments division provides international individual life insurance products in Japan, Korea, and other foreign countries; and offers proprietary and non-proprietary asset management, investment advice, and services to retail and institutional clients internationally. In addition, the company engages in real estate brokerage franchise business, which involves marketing its franchises to the real estate companies. Further, it provides institutional clients and government agencies with various services in connection with the relocation of their employees. Prudential Financial, Inc. was founded in 1875 and is headquartered in Newark, New Jersey.

Advisors' Opinion:

• [By Ben Levisohn]

  Shanker and Stefano also note that American International Group isn’t the only insurance stock getting pounded recently, as Ameriprise Financial (AMP), MetLife (MET) and Prudential Financial (PRU) have also been dumped by investors recently. They explain why:

• [By Ben Levisohn]

  Sometimes even a stodgy life insurer needs some love, and Merrill Lynch has provided it in spades to Prudential (PRU).

  NHLI via Getty Images Martin Brodeur plays at Prudential Center. Merrill Lynch makes the save. Or something like that.

  That’s because Merrill Lynch’s Seth Weiss and Ian Ryave decided to upgrade Prudential today. They explain why:

Hot Sliver Companies To Watch In Right Now: Sky Deutschland AG (SKYD)

Sky Deutschland AG is a Germany-based holding company, which operates a subscription television network in Germany and Austria. The Company manages television brands, including Sky Welt and Sky Welt Extra, as well as offers packages Film, Sport, Fussball Bundesliga (Germany football league), and HD (High Definition television), as well as pay-per-view service Sky Select and Sky Go. Furthermore, the Company offers Sky Hotel & Bars service, which provides the Company's services in public houses and bars. The Company offers approximately 70 television channels of various genres. Sky Select package enables watching selected movies at the specific time. Sky Go offers content on mobile devices, Internet and simultaneously on different television sets. The Company is also engaged in the purchase, sale and distribution of rights to film, series and television productions, the acquisition, sale and distribution of broadcasting rights for public events, among others. Advisors' Opinion:

• [By Inyoung Hwang]

  Sky Deutschland AG (SKYD) surged 5 percent to 7.55 euros, the highest price since September 2008. The pay-television said third-quarter ebitda climbed 19 percent to 29.2 million euros. Revenue jumped 19 percent from a year earlier to 392.7 million, topping analysts��estimates.

Hot Sliver Companies To Watch In Right Now: Galena Biopharma Inc (GALE)

Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).

The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.

In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.

The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.

The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.

Advisors' Opinion:

• [By Michael Douglass and David Williamson]

  Galena Biopharma� (NASDAQ: GALE  ) announced this morning that it has licensed the rights to sell Zuplenz for $5 million in stock and cash, in addition to royalties, milestones, and an upfront payment.

• [By Paul Ausick]

  Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analyst�� upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.

Hot Sliver Companies To Watch In Right Now: (NWBO)

Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer in the United States. Its technology platforms comprise dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company?s product candidates include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain that is in Phase II clinical trial for the treatment of glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. Its product candidates also comprise DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, which completed Phase I/II clinical trials for the treatment of resectable solid tumors. In addition, the company develops CXCR4 antibodies, which are involved in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung cancer, breast cancer, glioblastoma multiforme, colon cancer, melanoma, prostate, pancreatic, kidney, ovarian, and certain blood cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Advisors' Opinion:

• [By Smith On Stocks]

  Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.

Hot Sliver Companies To Watch In Right Now: Centerra Gold Inc (CAGDF.PK)

Centerra Gold Inc. (Centerra) is a gold mining company. The Company is engaged in the production of gold and related activities, including exploration, development, mining and processing in the Kyrgyz Republic, Mongolia, Turkey, China and the Russian Federation. The Company�� producing gold mines properties include Kumtor, in the Kyrgyz Republic (100%) and Boroo, in Mongolia (100%). Centerra�� development project includes Gatsuurt, in Mongolia. Its exploration projects include ATO, in Mongolia (100%); Oksut, in Turkey (100%); Kara Beldyr, in Russia (70%); Dvoinoy, in Russia (40%), and Ulaan Bulag, in Mongolia (100%). Kumtor gold mine is located in the Kyrgyz Republic, about 350 kilometers southeast of the capital Bishkek and about 60 kilometers north of the border with the People�� Republic of China. The Boroo gold mine is located in Mongolia some 110 kilometers to the northwest of the capital city of Ulaanbaatar. The Kara Beldyr project is a joint venture with Auriant Mining Company. Advisors' Opinion:

• [By Itinerant]

  Goldcorp, Newmont (NEM) or Agnico-Eagle use similar definitions. The important element here is the so-called 'sustaining capital expenditure', which is the capital required to sustain existing production levels. The table below is taken from the Agnico-Eagle presentation referenced above and provides a comparison of company-wide AISC for some of the major gold miners, including Goldcorp, Barrick Gold, Newmont Mining, Yamana Gold (AUY), Randgold (GOLD), Kinross (KGC), Agnico-Eagle Mines, Eldorado Gold (EGO), Goldfields and Centerra (CAGDF.PK). The difference between cash costs and AISC is significant. It is also important to note that these AISC are still noticeably below the present spot price for gold.

Hot Sliver Companies To Watch In Right Now: Kate Spade & Co (KATE)

Kate Spade & Co, formerly Fifth & Pacific Companies Inc, incorporated in January 1976, designs and markets a portfolio of retail-based, premium brands, including JUICY COUTURE, KATE SPADE and LUCKY BRAND. The Company also has a private brand jewelry design and development division, which markets brands through department stores and serves J.C. Penney Corporation, Inc. (JCPenney), through exclusive supplier agreements for the LIZ CLAIBORNE and MONET jewelry lines and Kohl's Corporation (Kohl's) through an exclusive supplier agreement for DANA BUCHMAN jewelry. It also has licenses for the LIZ CLAIBORNE NEW YORK brand, available at QVC and LIZWEAR, which is distributed through the club store channel. It maintains an 18.75% stake in MEXX, a European and Canadian apparel and accessories retail-based brand. As of December 31, 2011, the Company operated a total of 307 specialty retail stores under various Company trademarks, consisting of 285 retail stores within the United States and 22 retail stores outside of the United States (primarily in Europe and Canada). The Company operates in four segments: JUICY COUTURE segment, KATE SPADE segment, LUCKY BRAND segment, and Adelington Design Group & Other segment. In August 2013, Granite Real Estate Investment Trust closed its acquisition of a 600,000 square foot logistics-distribution facility in West Chester (Cincinnati), Ohio from the Company. In February 2014, the Company completed the sale of Lucky Brand Dungarees Inc.

JUICY COUTURE segment consists of the specialty retail, outlet, concession, wholesale apparel, wholesale non-apparel (including accessories, jewelry and handbags), e-commerce and licensing operations of its JUICY COUTURE brand. KATE SPADE segment consists of the specialty retail, outlet, wholesale apparel, wholesale non-apparel, e-commerce and licensing operations of its KATE SPADE and JACK SPADE brands. LUCKY BRAND segment consists of the specialty retail, outlet, wholesale apparel, wholesale non-apparel, e-commerce and licensing ! operations of its LUCKY BRAND. Adelington Design Group & Other segment consists of exclusive arrangements to supply jewelry for the DANA BUCHMAN, LIZ CLAIBORNE and MONET brands; the wholesale non-apparel operations of the TRIFARI brand and licensed KENSIE brand; the wholesale apparel and wholesale non-apparel operations of the licensed LIZWEAR brand and other brands, and the licensed LIZ CLAIBORNE NEW YORK brand.

JUICY COUTURE

The Company�� JUICY COUTURE brand offers luxurious, casual and fun women's and girl's apparel, as well as accessories and jewelry under various JUICY COUTURE trademarks. JUICY COUTURE products are sold through wholly owned specialty retail and outlet stores, select upscale specialty retail stores and department stores throughout the United States, through a network of distributors and owned and licensed retail stores in Asia, Canada, Europe, South America and the Middle East, as well as through its JUICY COUTURE e-commerce Website. In addition, JUICY COUTURE has existing licensing agreements for fragrances, footwear, optics, watches, swimwear, electronics cases and baby products.

KATE SPADE

The Company�� KATE SPADE brand offers fashion products (accessories, apparel and jewelry) for women and men under the KATE SPADE and JACK SPADE respectively. These products are sold primarily in the United States through wholly owned specialty retail and outlet stores, select specialty retail and upscale department stores, its operations in Brazil and the United Kingdom and through its KATE SPADE e-commerce Website, as well as through joint ventures in Japan and China and through a network of distributors in Asia. KATE SPADE's product line includes handbags, small leather goods, fashion accessories, jewelry and apparel. In addition, KATE SPADE has licensing agreements for footwear, optics, fragrances, tabletop products, legwear, electronics cases, bedding and stationery. JACK SPADE products include briefcases, travel bags, small leather go! ods and a! pparel.

LUCKY BRAND

The Company�� LUCKY BRAND offers an expanded assortment of men's and women's denim, woven and knit tops, dresses and sweaters, graphic tees, as well as accessories and jewelry, under various LUCKY BRAND. LUCKY BRAND products are available for sale at wholly owned specialty retail and outlet stores in the United States and Canada, select department and specialty stores and through the LUCKY BRAND e-commerce Website. LUCKY BRAND also has licensing agreements for fragrances, footwear, swimwear, eyewear and electronic cases.

Adelington Design Group & Other

The operations within the Company Adelington Design Group & Other segment consist of exclusive supplier arrangements to provide JCPenney with LIZ CLAIBORNE and MONET branded jewelry and Kohl's with DANA BUCHMAN-branded jewelry for two years; a license to produce and sell jewelry under the KENSIE brand name; a royalty free license for the LIZ CLAIBORNE NEW YORK brand; LIZWEAR, women's apparel available through the club store channel, and TRIFARI, a signature jewelry brand for women sold in mid-tier department stores.

The Company competes with Marc by Marc Jacobs, JCrew, Michael Kors, Pink, Coach, Diane von Furstenberg, Diesel, Guess, True Religion, 7 for all Mankind, Abercrombie & Fitch, and Tory Burch.

Advisors' Opinion:

• [By Mukesh Baghel]

  Luxury retailer Coach (NYSE: COH  ) has lost its wheels in 2014, while competitors Michael Kors (NYSE: KORS  ) and Kate Spade (NYSE: KATE  ) are chugging along nicely. Coach's bad times started when the company declared disappointing second-quarter results in late January. Its North American comps declined 13.6% while its overall revenue dropped 6%.

• [By Ted Cooper]

  There's a bargain in the premium aisle
  In investing, it rarely pays to buy what's already in fashion. While Michael Kors (NYSE: KORS  ) and Kate Spade (NYSE: KATE  ) trade at 24 times earnings, Coach is on sale for just 11 times earnings. Although Coach's stock is out of style, it represents a compelling bargain for long-term investors. Michael Kors and Kate Spade together generate the same amount of revenue as Coach, yet their combined enterprise value is twice the latter's enterprise value.